



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

November 21, 2022

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

Dear Sir/ Madam,

In reference to the proposed acquisition of biosimilars assets of Viatrix Inc., by Biocon Biologics Limited (“**BBL**”), subsidiary of Biocon Limited, please be informed that BBL and its subsidiaries have executed a Debt Facility Agreement which is classified as a Sustainability-linked Loan (SLL) amounting to US\$1.2 billion on November 20, 2022, the proceeds of which shall be used for funding the acquisition of Viatrix Inc.’s biosimilars business and acquisition related expenses.

We request you to take this on record.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776